Legal Protection Of Pharmaceutical Patents Amid Compulsory Licensing Policies.

18 Mar 2026 --
0 Comments

1. Background: Pharmaceutical Patents and Compulsory Licensing

Pharmaceutical patents give the inventor exclusive rights to make, use, and sell a drug for a limited period (usually 20 years under TRIPS—Trade-Related Aspects of Intellectual Property Rights). However, governments can grant compulsory licenses (CLs) under certain circumstances:

Public health crises (like HIV/AIDS or COVID-19)
Anti-competitive practices
Emergency or national need

This allows generic manufacturers to produce patented drugs without the consent of the patent holder, typically paying reasonable royalties.

The tension: patent rights vs public health needs. Courts worldwide have addressed this balance.

2. Key Cases on Pharmaceutical Patents and Compulsory Licensing

Case 1: Novartis AG v. Union of India (2013) – India

Facts:

Novartis sought a patent for its cancer drug Glivec in India.
India’s patent law includes Section 3(d), preventing “evergreening” (minor modifications of existing drugs) from getting new patents.

Issue:

Can Novartis get a patent for an updated version of a known drug?

Judgment:

Supreme Court of India denied the patent.
Held that Glivec was not sufficiently innovative under Section 3(d).

Significance:

Reinforced that patent protection is not absolute in pharmaceuticals.
Paved the way for generic versions of drugs to be produced in India, promoting access to affordable medicines.

Case 2: Bayer Corporation v. Natco Pharma Ltd. (2012) – India

Facts:

Natco applied for a compulsory license for Sorafenib (Nexavar), a cancer drug patented by Bayer.
Price was very high (~$5,000/month).

Judgment:

India’s first compulsory license granted under Section 84 of the Indian Patents Act, 1970.
Natco could produce the generic version at a fraction of the cost (~$175/month).

Significance:

Showed that public health can justify compulsory licensing.
Confirmed that high prices and lack of availability are valid grounds for compulsory licensing in India.

Case 3: Roche v. Cipla (2008) – India

Facts:

Cipla manufactured generic HIV/AIDS drugs patented by Roche.
Roche claimed patent infringement.

Judgment/Outcome:

Cipla argued that the drugs were for essential public health needs and pricing was much lower than the patented version.
Indian courts allowed generic production under strict conditions, citing affordability and accessibility.

Significance:

Highlighted India’s pro-patient stance in patent disputes.
Demonstrated that pharmaceutical patents are not absolute, especially for life-saving medicines.

Case 4: Compulsory Licensing of Bayer’s Sorafenib – TRIPS Context

This is related to Case 2 but worth examining in international law context:

Facts:

TRIPS Agreement allows countries to issue CLs for national emergencies or anti-competitive practices.
India justified the CL citing high cost and lack of affordability.

Significance:

Confirms that TRIPS flexibilities protect public health.
Courts can balance patent protection and compulsory licenses without violating international law.

Case 5: Merck Sharp & Dohme Corp. v. Glenmark Pharmaceuticals (2015) – India

Facts:

Glenmark applied for a generic version of Merck’s Sitagliptin (diabetes drug).
Merck claimed patent infringement.

Judgment:

Indian Patent Office rejected Merck’s patent claim in part, noting the drug was already known and lacked inventive step.

Significance:

Reinforced strict scrutiny for pharmaceutical patents.
Emphasized that patents cannot be extended unjustifiably, allowing generic competition.

Case 6: Thailand Compulsory Licensing of HIV Drugs (2007) – Thailand

Facts:

Thailand issued CLs for efavirenz and lopinavir/ritonavir due to public health need.
U.S. pharmaceutical companies protested, claiming TRIPS violation.

Outcome:

Thailand invoked Doha Declaration on TRIPS and Public Health (2001): countries can issue CLs to ensure public health.

Significance:

Set an international precedent for CLs.
Demonstrated that countries could override patents during health crises legally.

3. Principles Emerging from These Cases

Public Health Overrides: Courts prioritize access to essential medicines over strict patent rights.
Preventing Evergreening: Patents cannot be extended by minor modifications (Novartis case).
Affordable Pricing as a Justification: High prices and limited accessibility justify CLs (Bayer v. Natco).
International Law Compliance: TRIPS flexibilities allow countries to issue CLs without breaching WTO obligations.
Patent Examination Standards: Courts ensure patents meet novelty, inventive step, and industrial applicability criteria before enforcing exclusivity.

4. Conclusion

Legal protection of pharmaceutical patents is robust but not absolute. Compulsory licensing acts as a check against monopolies, ensuring life-saving drugs are accessible and affordable. Cases from India and Thailand illustrate how courts balance innovation incentives for pharmaceutical companies with humanitarian and public health needs.